Immunovant presents corporate overview at J.P. Morgan Healthcare Conference; no new data disclosed

Immunovant, Inc.

Presentation on January 14, 2025 covers autoimmune pipeline and tailored science approach.
No specific clinical results, financial updates, or guidance changes provided in the filing.
Filed under Regulation FD; presentation not incorporated by reference into SEC filings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.